(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...

The initial phase of the collaboration will focus on clinical decision-making processes, such as dose selection, ...

As part of the collaboration, the drugmaker will use Immunai's AI model of the immune system and machine learning for ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics.

Monday, AstraZeneca Plc AZN released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...

James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the ...

AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...